Novartis and Medicines for Malaria Venture announce decision to move to Phase 3 study for novel ganaplacide/lumefantrine-SDF combination in adults and children with malaria

·    Novartis and Medicines for Malaria Venture (MMV) announce decision to move to Phase 3 study for novel non-artemisinin combination to treat uncomplicated

Related Keywords

Singapore ,Sweden ,Germany ,Burkina Faso ,Niger ,United States ,Netherlands ,Mali ,Kigali ,W09 ,Rwanda ,Gabon ,Uganda ,Switzerland ,France ,America ,Swiss ,Isabella Zinck ,African Engl ,Arzum Ustun ,Nicole Zinsli Somm ,Samir Shah ,Sujata Vaidyanathan ,Parag Mahanti ,Julie Masow ,Neil Henderson ,Africa Burkina Faso ,Sloan Simpson ,Paul Barasa ,Alina Levchuk ,Linkedin ,Twitter ,Novartis Global Health Communications ,Genomics Institute Of The Novartis Research Foundation ,Novartis External Communications ,Novartis ,African Media Agency ,Singapore Economic Development Board ,European Union ,Facebook ,Wellcome ,Head Global Health Development Unit ,Drug Administration ,World Health Organization ,Public Health Institute ,Novartis Us External Communications ,Saharan Africa Communications ,Countries Clinical Trials Partnership ,Youtube ,Novartis Institute For Tropical Diseases ,Malaria Venture ,Both Phase ,Developing Countries Clinical Trials Partnership ,Chief Scientific Officer ,Fast Track Designation ,Orphan Drug Designation ,Eastern Africa ,World Malaria Report ,Wellcome Trust ,Novartis Institute ,Tropical Diseases ,Genomics Institute ,Novartis Research Foundation ,Swiss Tropical ,Public Health ,Kigali Summit ,Neglected Tropical Diseases ,West African Network ,Clinical Trials ,Antimalarial Drugs ,Health Organization ,Media Relations ,External Communications ,Global Health Communications ,Investor Relations ,African Media ,